FPM are supporting a series of three webinars designed to help medical directors and other leaders in embedding the ABPI Principles within their organisations.
These new Principles have been approved together with the 2021 ABPI Code of Practice, which comes into operation on 1 July 2021.
The Principles embody the spirit of the Code and cover four areas:
- transparency and
The webinars will review best practice in fostering principle-based ways of working and will focus on the specific principles. The sessions will be interactive and allow attendees to share their experiences and ask questions.
This is the first webinar in this series, introducing the role of the principles in underpinning the ABPI Code and system of self regulation.
These webinars are free to attend, and all FPM members are welcome to take part.
- via the ABPI GoWebinar booking portal
- Joining instructions will be sent via GoToWebinar
Session 1 – Thur 15 April, 10:15 to 11:15 (GMT) – Introduction
To launch the series and frame the role of the principles in underpinning our Code and system of self-regulation; introducing the challenges of embedding, championing and following the ABPI principles within corporate culture.
- Haseeb Ahmed, ABPI President
- Berkeley Phillips, Medical Director, Pfizer
- Nick Broughton FFPM, Pharma Ethos
Chair: Sheuli Porkess FFPM, Chair of Policy and Communications Group
Session 2 – Thursday 6 May, 9:00 to 10:00 – Patients
To focus on the principle of benefiting patients: what does good look like, and how effective is the pharma industry at being truly patient-centric?
- Natasha Ratcliffe, Research Involvement Manager, Parkinson’s UK
- Bryn Jones MFPM, Patient Affairs Director, Viiv
- Colette Goldrick, Executive Director, Strategy & Partnerships, ABPI
Session 3 – Thursday 20 May, 10:00 to 11:00 – Integrity, Transparency and Respect
To focus on the three principles of integrity, transparency and respect, and how we can embed them; the expectations of society and where (and how) the pharma industry is meeting these expectations; the relationship between ethical behaviour and trust.
- Malcolm Brown FFPM, Therapeutic Area Head, Global Medical Affairs, Astellas
- Ian Peters, Director, Institute of Business Ethics
- Tom Fife-Schaw, Research Director, Ipsos MORI
The views, information, or opinions expressed during FPM events and training are those of the individuals involved and do not necessarily represent those of the Faculty of Pharmaceutical Medicine. We value inclusivity, equality and diversity, and work hard to promote these whenever possible in all of our activities. We welcome your comments and feedback: email@example.com